Why Boston Scientific (BSX) Outpaced the Stock Market Today

Boston Scientific (BSX) closed at $104.33 in the latest trading session, marking a +1.09% move from the prior day. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.27%. Prior to today's trading, shares of the medical device manufacturer had gained 3.47% outpaced the Medical sector's loss of 1.34% and lagged the S&P 500's gain of 3.97%.Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on July 23, 2025. On that day, Boston Scientific is projected to report earnings of $0.72 per share, which would represent year-over-year growth of 16.13%. Meanwhile, our latest consensus estimate is calling for revenue of $4.89 billion, up 18.69% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.91 per share and revenue of $19.5 billion. These totals would mark changes of +15.94% and +16.42%, respectively, from last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Boston Scientific is currently a Zacks Rank #2 (Buy). Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 35.4. This valuation marks a premium compared to its industry average Forward P/E of 19.64. Meanwhile, BSX's PEG ratio is currently 2.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices. The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 41% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks